Suppr超能文献

非血缘供者及人类白细胞抗原(HLA)相合的同胞造血干细胞移植可治愈慢性肉芽肿病,长期预后及生长情况良好。

Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.

作者信息

Soncini Elena, Slatter Mary A, Jones Laura B K R, Hughes Stephen, Hodges Stephen, Flood Terence J, Barge Dawn, Spickett Gavin P, Jackson Graham H, Collin Matthew P, Abinun Mario, Cant Andrew J, Gennery Andrew R

机构信息

Department of Paediatric Immunology, Newcastle upon Tyne Hospitals Foundation Trust, Newcastle upon Tyne, UK.

出版信息

Br J Haematol. 2009 Apr;145(1):73-83. doi: 10.1111/j.1365-2141.2009.07614.x. Epub 2009 Feb 16.

Abstract

Chronic granulomatous disease (CGD) causes recurrent infection and inflammatory disease. Despite antimicrobial prophylaxis, patients experience frequent hospitalisations and 50% mortality by 30 years. Haematopoietic stem cell transplantation (HSCT) can cure CGD with resolution of infection and colitis. This study reports the survival and long-term outcome in 20 conditioned patients treated between 1998 and 2007, using 10 matched sibling (MSD) and 10 unrelated donors (URD). Age at HSCT, graft-versus-host disease (GvHD), growth, and outcome were analysed. Fourteen had > or = 1 invasive infection, 10 had colitis and seven had growth failure before HSCT. Median age at transplantation was 75 months (range 15 months-21 years). Eighteen (90%) were alive 4-117 months (median 61) after HSCT with normal neutrophil function. Two died from disseminated fungal infection. Two experienced significant chronic GvHD, with continuing sequelae in 1. Colitis resolved within 8 weeks of HSCT. Mean weight and height for age Z scores on recovery from HSCT rose significantly (P < 0.001). HSCT with MSD or URD gave excellent engraftment and survival, remission of colitis and catch-up growth, with low incidence of significant GvHD. Transplant-associated complications were restricted to those with pre-existing infection or inflammation, supporting the argument for early HSCT for more CGD patients with a well matched donor.

摘要

慢性肉芽肿病(CGD)可导致反复感染和炎症性疾病。尽管采取了抗菌预防措施,但患者仍频繁住院,到30岁时死亡率达50%。造血干细胞移植(HSCT)可治愈CGD,使感染和结肠炎得到缓解。本研究报告了1998年至2007年间接受治疗的20例患者的生存情况和长期预后,其中10例使用匹配的同胞供者(MSD),10例使用无关供者(URD)。分析了HSCT时的年龄、移植物抗宿主病(GvHD)、生长情况和预后。14例患者在HSCT前发生过≥1次侵袭性感染,10例有结肠炎,7例有生长发育迟缓。移植时的中位年龄为75个月(范围15个月至21岁)。18例(90%)患者在HSCT后4至117个月(中位时间61个月)存活,中性粒细胞功能正常。2例死于播散性真菌感染。2例发生严重慢性GvHD,其中1例有持续后遗症。结肠炎在HSCT后8周内缓解。HSCT后恢复时,年龄别体重和身高Z评分均值显著上升(P<0.001)。使用MSD或URD进行HSCT可实现良好的植入和生存,结肠炎缓解且实现追赶生长,严重GvHD的发生率较低。移植相关并发症仅限于那些已有感染或炎症的患者,这支持了为更多有匹配良好供者的CGD患者尽早进行HSCT的观点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验